Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Estonia

Coordination and Support Action · Running

CALM6A First-in-class bi-functional METTL3-14 complex activator restoring m6A RNA balance for disease-modifying treatment of anxiety

Coordinator
Oü Chemestmed, Estonia
Runs
1 July 2026 to 30 June 2028
Status
Running
EU funding
€446k
Total cost
—
Partners
1 organisations in 1 countries
Type
Coordination and Support Action
Grant agreement
101310074

What the project is doing

In the project's own words, from its summary on CORDIS.

Generalised anxiety disorder (GAD) affects over 5% of Europeans, yet current treatments are slow, often poorly tolerated, and frequently fail to provide lasting relief. No approved therapies target the molecular pathways underlying stress dysregulation. CALM6A introduces a first-in-class small-molecule approach designed to activate the METTL3–14 RNA methylation complex, a central regulator of m6A-dependent gene expression linked to neuronal plasticity and stress adaptation.

Chemestmed’s discovery studies show that activating this complex restores m6A levels, normalises monoamine signalling, and produces anxiolytic-like effects in validated preclinical models. This project advances CALM6A from TRL 4 to TRL 5 through an integrated scientific and translational programme. It will design and synthesise bifunctional METTL3–14 activators with improved potency and pharmacokinetic properties; validate their biological activity using enzymatic, biophysical, and neuronal-cell assays; and generate preliminary non-GLP toxicology and pharmacokinetic data, including brain penetration, to select a lead compound suitable for later GLP planning and regulatory consultation.

Biomarker-linked readouts will ensure mechanism-based differentiation and provide a solid foundation for future clinical progression. In parallel, the project will establish key elements for downstream translation. A Target Product Profile will be refined with external experts, pharmaceutical partners, and investors. Intellectual-property protection will be strengthened through additional filings and portfolio review.

A business plan, financial model, and investor-ready package will be developed, together with a regulatory and clinical-readiness roadmap defining the next steps toward IND/CTA preparation. By combining mechanistic innovation with rigorous validation and early market alignment, CALM6A aims to enable the future clinical development of a new therapeutic option for anxiety disorders.

Topics

Who is involved

OrganisationCityCountryRole
Oü ChemestmedTartu LinnEstoniaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI